ZFP57 suppress proliferation of breast cancer cells through down-regulation of MEST-mediated Wnt/β-catenin signalling pathway

Cell Death & Disease
Lie ChenMingjie Zheng

Abstract

Activation of oncogenes by promoter hypomethylation plays an important role in tumorigenesis. Zinc finger protein 57 (ZFP57), a member of KRAB-ZFPs, could maintain DNA methylation in embryonic stem cells (ESCs), although its role and underlying mechanisms in breast cancer are not well understood. In this study, we found that ZFP57 had low expression in breast cancer, and overexpression of ZFP57 could inhibit the proliferation of breast cancer cells by inhibiting the Wnt/β-catenin pathway. MEST was validated as the direct target gene of ZFP57 and MEST may be down-regulated by ZFP57 through conserving DNA methylation. Furthermore, overexpression of MEST could restore the tumour-suppressed and the Wnt/β-catenin pathway inactivated effects of ZFP57. ZFP57-MEST and the Wnt/β-catenin pathway axis are involved in breast tumorigenesis, which may represent a potential diagnostic biomarker, and provide a new insight into a novel therapeutic strategy for breast cancer patients.

References

Dec 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·G R Martin
Aug 24, 1999·Cell·J F BrombergJ E Darnell
Nov 2, 2001·Nature·T ReyaI L Weissman
Feb 18, 2004·Nature Reviews. Cancer·Hua Yu, Richard Jove
Mar 6, 2004·Science·W James Nelson, Roel Nusse
Nov 19, 2004·Nature·Philip A BeachyDavid M Berman
Feb 26, 2005·Science·Takashi SakataniAndrew P Feinberg
Apr 23, 2005·Biochemical and Biophysical Research Communications·Tadayuki AkagiTakashi Yokota
Sep 13, 2005·Cell·Laurie A BoyerRichard A Young
Aug 26, 2006·Endocrine Reviews·Amir Abbas SamaniPnina Brodt
Jan 12, 2007·Development·Hitoshi Niwa
Oct 16, 2008·Developmental Cell·Xiajun LiAnne C Ferguson-Smith
Jul 22, 2009·Developmental Cell·Bryan T MacDonaldXi He
Jan 19, 2010·Proceedings of the National Academy of Sciences of the United States of America·Andrew P Feinberg, Rafael A Irizarry
May 25, 2010·Epigenomics·Melanie Ehrlich
Jun 16, 2012·Mutation Research·Lien Van De VoordeMarijn Speeckaert
Feb 13, 2013·Nature Reviews. Genetics·Zachary D Smith, Alexander Meissner
Apr 16, 2014·The Lancet Oncology·Paul E GossArlene Chan
May 14, 2014·Seminars in Cancer Biology·Cara JamiesonBeric R Henderson
Jun 23, 2015·PloS One·Yosuke HiramukiAtsuko Sehara-Fujisawa
Jun 30, 2015·International Journal of Obesity : Journal of the International Association for the Study of Obesity·M KarbienerM Scheideler
Jun 7, 2016·The Journal of Pathology·Arnoud BootTom van Wezel

❮ Previous
Next ❯

Citations

Oct 20, 2019·Journal of Molecular Biology·Amelia J HodgesBethany A Buck-Koehntop
Mar 7, 2021·International Journal of Molecular Sciences·Joanna SobocińskaUrszula Oleksiewicz

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
immunoprecipitation
fluorescence microscopy
xenograft
electrophoresis
transfection
Flow
RNA-seq
ChIP
Flow cytometry

Software Mentioned

Graphpad Prism
SPSS
TOPFlash

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Adherens Junctions

An adherens junction is defined as a cell junction whose cytoplasmic face is linked to the actin cytoskeleton. They can appear as bands encircling the cell (zonula adherens) or as spots of attachment to the extracellular matrix (adhesion plaques). Adherens junctions uniquely disassemble in uterine epithelial cells to allow the blastocyst to penetrate between epithelial cells. Discover the latest research on adherens junctions here.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cadherins and Catenins

Cadherins (named for "calcium-dependent adhesion") are a type of cell adhesion molecule (CAM) that is important in the formation of adherens junctions to bind cells with each other. Catenins are a family of proteins found in complexes with cadherin cell adhesion molecules of animal cells: alpha-catenin can bind to β-catenin and can also bind actin. β-catenin binds the cytoplasmic domain of some cadherins. Discover the latest research on cadherins and catenins here.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.